替罗非班用于无大中血管闭塞的卒中
RESCUE BT2多中心试验在中国纳入606例替罗非班组、571例阿司匹林组无大中血管闭塞的缺血性卒中患者,NIHSS≥5分且至少一肢中重度无力,涵盖不适合溶栓/取栓、症状进展、溶栓后早期恶化或溶栓无改善四种临床情形。替罗非班静脉给药联合口服安慰剂,对照组口服阿司匹林100 mg/日联合静脉安慰剂,均用2天,之后所有患者口服阿司匹林至90天。主要疗效终点90天mRS 0–1分为29.1% vs 22.2%(校正RR 1.26,95%CI 1.04–1.53,P=0.02)。症状性颅内出血替罗非班组1.0%、阿司匹林组0%,死亡率相似,次要终点结果与主要分析总体不一致。
要点
- 无大中血管闭塞的缺血性卒中、NIHSS≥5分且至少一肢中重度无力者,替罗非班90天mRS 0–1分29.1% vs 阿司匹林22.2%(aRR 1.26,95%CI 1.04–1.53,P=0.02)。
- 症状性颅内出血替罗非班组1.0% vs 阿司匹林组0%,死亡率两组相似。
- 次要终点(90天功能独立、生活质量评分)结果与主要分析总体不一致。
- 纳入四种临床情形:不适合溶栓/取栓且末次正常24小时内、发病24–96小时症状进展、溶栓后早期神经恶化、溶栓后4–24小时无改善。
- 替罗非班静脉给药联合口服安慰剂,对照为口服阿司匹林100 mg/日联合静脉安慰剂,均2天,之后全部口服阿司匹林至90天。
适用人群与场景
- 中国多中心试验纳入的缺血性卒中患者,无大中血管闭塞证据,NIHSS评分≥5分且至少一肢中重度无力。
- 四种临床情形之一:不适合溶栓或取栓且末次正常24小时内;发病24–96小时症状进展;溶栓后早期神经恶化;溶栓后4–24小时无改善。
- 多数患者为推测动脉粥样硬化性小梗死。
诊断标准与关键阈值
- 无大中血管完全闭塞证据。
- NIHSS评分≥5分且至少一肢中重度无力。
- mRS评分范围0(无症状)至6(死亡),主要终点为90天mRS 0或1分。
处置流程与药物剂量
- 替罗非班组:静脉替罗非班联合口服安慰剂,疗程2天;之后所有患者口服阿司匹林至90天(原文未写明替罗非班剂量与给药频次)。
- 阿司匹林组:口服阿司匹林100 mg/日联合静脉安慰剂,疗程2天;之后所有患者口服阿司匹林至90天。
研究设计与关键结果
- 多中心试验,替罗非班组606例、阿司匹林组571例;主要疗效终点90天mRS 0–1分替罗非班29.1% vs 阿司匹林22.2%(校正RR 1.26,95%CI 1.04–1.53,P=0.02)。
- 症状性颅内出血替罗非班组1.0% vs 阿司匹林组0%;死亡率两组相似。
- 次要终点(90天功能独立、生活质量评分)结果与主要分析总体不一致。
证据类型、等级与局限
- 多中心试验(RESCUE BT2,中国临床试验注册号ChiCTR2000029502),由国家自然科学基金资助。
- 局限:次要终点结果与主要分析总体不一致。
对床旁实践的改变
- 对无大中血管闭塞、NIHSS≥5分且至少一肢中重度无力的缺血性卒中患者,静脉替罗非班较口服阿司匹林100 mg/日可能提高90天优良结局比例(29.1% vs 22.2%,aRR 1.26)。
- 替罗非班组症状性颅内出血1.0% vs 阿司匹林组0%,死亡率相似。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied.
METHODS: In a multicenter trial in China, we enrolled patients with ischemic stroke without occlusion of large or medium-sized vessels and with a National Institutes of Health Stroke Scale score of 5 or more and at least one moderately to severely weak limb. Eligible patients had any of four clinical presentations: ineligible for thrombolysis or thrombectomy and within 24 hours after the patient was last known to be well; progression of stroke symptoms 24 to 96 hours after onset; early neurologic deterioration after thrombolysis; or thrombolysis with no improvement at 4 to 24 hours. Patients were assigned to receive intravenous tirofiban (plus oral placebo) or oral aspirin (100 mg per day, plus intravenous placebo) for 2 days; all patients then received oral aspirin until day 90. The primary efficacy end point was an excellent outcome, defined as a score of 0 or 1 on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]) at 90 days. Secondary end points included functional independence at 90 days and a quality-of-life score. The primary safety end points were death and symptomatic intracranial hemorrhage.
RESULTS: A total of 606 patients were assigned to the tirofiban group and 571 to the aspirin group. Most patients had small infarctions that were presumed to be atherosclerotic. The percentage of patients with a score of 0 or 1 on the modified Rankin scale at 90 days was 29.1% with tirofiban and 22.2% with aspirin (adjusted risk ratio, 1.26; 95% confidence interval, 1.04 to 1.53, P = 0.02). Results for secondary end points were generally not consistent with the results of the primary analysis. Mortality was similar in the two groups. The incidence of symptomatic intracranial hemorrhage was 1.0% in the tirofiban group and 0% in the aspirin group.
CONCLUSIONS: In this trial involving heterogeneous groups of patients with stroke of recent onset or progression of stroke symptoms and nonoccluded large and medium-sized cerebral vessels, intravenous tirofiban was associated with a greater likelihood of an excellent outcome than low-dose aspirin. Incidences of intracranial hemorrhages were low but slightly higher with tirofiban. (Funded by the National Natural Science Foundation of China; RESCUE BT2 Chinese Clinical Trial Registry number, ChiCTR2000029502.).
参考来源
- Zi W, Song J, Kong W, et al. Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion. N Engl J Med. 2023. PMID: 37256974. doi:10.1056/NEJMoa2214299
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。